ClinicalTrials.gg
RecruitingNCT06850727Updated Feb 11, 2026

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of OD-07656 and Vedolizumab in Ulcerative Colitis (UC) and UC - Ulcerative Colitis, sponsored by Odyssey Therapeutics. Recruiting at 32 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Odyssey Therapeutics · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.

Planned enrollment
182nd of 215
57 · median 196
Started
2025
with 18 others
Phase 2
104 of 221
15 open now
Primary completion
2026-04
later than 12 of 64 live
Registered
196th of 221
by date

Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 182nd largest by planned enrollment of the 215 interventional ones that give a count, is one of 19 that started in 2025, is one of 104 in phase 2, reaches primary completion later than 12 of the 64 other live ones, and was the 196th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Colitis, Ulcerative with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • UC - Ulcerative Colitis

Keywords

  • Ulcertative colitis
  • Inflammatory Bowel Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a confirmed diagnosis of ulcerative colitis (UC)
  • Has moderate to severely active UC as defined by the 3-component Modified Mayo clinic score
  • Has an inadequate response, loss of response, or intolerance/medical to at least one of the following therapies: oral aminosalicylates, , , anti-tumor necrosis factor biologic, anti-interleukin 12/23 biologic, Janus kinase inhibitors, or sphingosine-1-phosphate (S1P) modulators

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has diagnosis of Crohn's disease or indeterminate colitis
  • Has had extensive colonic resection
  • Has colostomy or ileostomy
  • Has uncontrolled primary sclerosing cholangitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    OD-07656 Dosing Regimen 1

    Open Label, Oral, twice daily dose

    Drug: OD-07656 · Drug: Vedolizumab

  • Experimental
    OD-07656 Dosing Regimen 2

    Randomized, Oral, twice daily dose

    Drug: OD-07656 · Drug: Vedolizumab

  • Experimental
    OD-07656 Dosing Regimen 3

    Randomized, Oral, twice daily dose

    Drug: OD-07656 · Drug: Vedolizumab

Interventions

  • DrugOD-07656

    Experimental intervention

  • Active standard of care comparator

06

What researchers measure

Primary outcomes

  1. Change in 3-component modified Mayo Clinic Score (MMCS) from baseline to after treatment with OD-07656

    The 3-component MMCS ranges from 0 to 9 and is composed of endoscopic assessment, rectal bleeding and stool frequency subscores with each of the components ranging from 0 to 3, with higher scores indicating more severe disease.

    Time frame: Baseline and 12 weeks

  2. Incidence of treatment-emergent adverse events (TEAEs) and treatment discontinuations due to TEAEs with OD-07656 treatment

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Proportion of participants who achieve clinical remission

    Clinical remission is based on the MMCS and is defined as endoscopic subscore of 0 or 1, rectal bleeding subscore of 0 and stool frequency subscore of 0 or 1 and not greater than baseline.

    Time frame: Baseline and 12 weeks

  2. Proportion of participants who achieve clinical remission with vedolizumab treatment, following OD-07656 treatment

    Clinical remission is based on the MMCS and is defined as endoscopic subscore of 0 or 1, rectal bleeding subscore of 0 and stool frequency scubscore of 0 or 1 and not greater than baseline.

    Time frame: Baseline and 50 weeks

07

Study locations

32 of 32 sites recruiting
  • Sunshine Coast University
    Birtinya, Australia
    Recruiting
    • Study Coordinator · Contact
  • Eastern Health
    Box Hill, Australia
    Recruiting
    • Study Coordinator · Contact
  • Coastal Digestive Health
    Maroochydore, Australia
    Recruiting
    • Study Coordinator · Contact
  • Alfred Health
    Melbourne, 3004, Australia
    Recruiting
    • Study Coordinator · Contact
  • Fiona Stanley Hospital
    Murdoch, 6150, Australia
    Recruiting
    • Study Coordinator · Contact
  • Royal Melbourne Hospital
    Parkville, Australia
    Recruiting
    • Study Coordinator · Contact
  • Medical University of Graz
    Graz, Austria
    Recruiting
    • Study Coordinator · Contact
  • CHUM
    Montreal, H2X OA9, Canada
    Recruiting
    • Study Coordinator · Contact
  • Montreal General Hospital/McGill University
    Montreal, Canada
    Recruiting
    • Study Coordinator · Contact
  • CHUM - Pavillon R
    Polička, 1549, Czechia
    Recruiting
    • Study Coordinator · Contact
  • Jordan University Hospital
    Amman, 11942, Jordan
    Recruiting
    • Study Coordinator · Contact
  • The Specialty Hospital (TSH) / Advanced Clinical Center
    Amman, Jordan
    Recruiting
    • Study Coordinator · Contact
  • Irbid Specialty Hospital
    Irbid, 21110, Jordan
    Recruiting
    • Study Coordinator · Contact
  • The Hospital of Lithuanian University of Health Sciences
    Kaunas, Lithuania
    Recruiting
    • Study Coordinator · Contact
  • IMSP Spitalul Clinic Republican Timofei Moneaga
    Chisinau, Md-2025, Moldova
    Recruiting
    • Study Coordinator · Contact
  • PCRN Auckland
    Auckland, 0622, New Zealand
    Recruiting
    • Study Coordinator · Contact
  • PCRN Christchurch
    Christchurch, 0622, New Zealand
    Recruiting
    • Study Coordinator · Contact
  • PCRN Waikato
    Hamilton, 3200, New Zealand
    Recruiting
    • Study Coordinator · Contact
  • PCRN Tasman
    Nelson, 7011, New Zealand
    Recruiting
    • Study Coordinator · Contact
  • PCRN Wellington
    Upper Hutt, 5018, New Zealand
    Recruiting
    • Study Coordinator · Contact
  • Centrum Medyczne
    Bydgoszcz, Poland
    Recruiting
    • Study Coordinator · Contact
  • Centrum Medyczne LukaMed
    Chojnice, Poland
    Recruiting
    • Study Coordinator · Contact
  • Vita Longa Sp. z.o.o.
    Katowice, Poland
    Recruiting
    • Study Coordinator · Contact
  • Centrum Medyczne Medyk
    Rzeszów, Poland
    Recruiting
    • Study Coordinator · Contact
  • Endoskopia Sp. z.o.o
    Sopot, Poland
    Recruiting
    • Study Coordinator · Contact
  • Nowe zdrowie-CK, Kiełtucki
    Staszów, Poland
    Recruiting
    • Study Coordinator · Contact
  • Medical Network Company
    Warsaw, Poland
    Recruiting
    • Study Coordinator · Contact
  • Penta Hospitals Przychodnie
    Wroclaw, 54-239, Poland
    Recruiting
    • Study Coordinator · Contact
  • Regional Clinical Hospital
    Ivano-Frankivsk, 76008, Ukraine
    Recruiting
    • Study Coordinator · Contact
  • Medical centre of ARENSIA Exploratory Medicine LCC
    Kyiv, 01135, Ukraine
    Recruiting
    • Study Coordinator · Contact
  • Danylo Halytsky Lviv National Medical University
    Lviv, 79000, Ukraine
    Recruiting
    • Study Coordinator · Contact
  • Lviv Regional Clinical Hospital
    Lviv, 79010, Ukraine
    Recruiting
    • Study Coordinator · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2026, 10 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 10 months is below that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2025
First posted
Feb 27, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Nov 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06850727
Lead sponsor
Odyssey Therapeutics
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Jun 2, 2025
Primary completion
Apr 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

Head of Clinical Operations
Contact
clinicaltrials@odysseytx.com
857-393-6160
Chief Medical Officer
study director · Odyssey Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion